Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Ann Oncol Ann Oncol 2022 2022 33 33 12 12 1250 1250 1268 1268 10.1016/j.annonc.2022.09.159 10.1016/j.annonc.2022.09.159 supplied-pmid 36228963? The gene discussed is BRCA1; the disease is breast carcinoma.